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Background: Rheumatoid arthritis (RA) is a chronic autoimmune condition that results in pain and disability.
Patients with RA have a decreased functional ability and are forced into a sedentary lifestyle and as such, these
patients often become predisposed to poor bone health. Patients with RA may also experience a decreased health
related quality of life (HRQoL) due to their disease. Whole body vibration (WBV) is a form of exercise that stimulates
bone loading through forced oscillation. WBV has also been shown to decrease pain and fatigue in other rheumatic
diseases, as well as to increase muscle strength. This paper reports on the development of a semi randomised
controlled clinical trial to assess the impact of a WBV intervention aiming to improve functional ability, attenuate
bone loss, and improve habitual physical activity levels in patients with RA.
Methods/Design: This study is a semi randomised, controlled trial consisting of a cohort of patients with
established RA assigned to either a WBV group or a CON (control) group. Patients in the WBV group will undergo
three months of twice weekly intermittent WBV sessions, while the CON group will receive standard care and
continue with normal daily activities. All patients will be assessed at baseline, following the three month
intervention, and six months post intervention. Main outcomes will be an improvement in functional ability as
assessed by the HAQ. Secondary outcomes are attenuation of loss of bone mineral density (BMD) at the hip and
changes in RA disease activity, HRQoL, habitual physical activity levels and body composition.
Discussion: This study will provide important information regarding the effects of WBV on functional ability and
BMD in patients with RA, as well as novel data regarding the potential changes in objective habitual physical
activity patterns that may occur following the intervention. The sustainability of the intervention will also be
assessed.
Trial registration: PACTR201405000823418 (19/05/2014).
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Rheumatoid Arthritis (RA) is the most common, chronic
autoimmune disease. It results in joint swelling, tender-
ness and destruction of the synovial joints, pain, severe
disability, and decreased functional ability [1]. RA occurs
in 1% of people worldwide, with the prevalence being
two times higher in women than in men [2].
The health assessment questionnaire (HAQ)- a disease
specific measure of functional ability in RA, is a widely
used outcome measures for RA [3]. A large qualitative
study conducted in female patients with RA found that
patients report pain and decreased functional ability as
having the most widespread effect on their daily lives
[4]. Inability to perform normal daily activities not only
decreases health related quality of life (HRQoL), but also
further perpetuates a sedentary lifestyle. HAQ scores
have been shown to be improved in patients with RA
who have participated in exercise interventions aimed at
increasing their regular levels of physical activity [5].
Physical activity as a functional measure of HRQoL
can be difficult to assess. Commonly used questionnaires
and recall diaries are subjective [6] and rely on fluency
in the English language. Accelerometers are thus grow-
ing in popularity as an objective way to measure physical
activity, especially in healthy populations [7]. Accelerom-
eters are small, unobtrusive and comfortable, and meas-
ure acceleration of the limb to which they are attached
by detecting low frequency (0.5-3.2 Hz) gravitational
forces (0.05-2.0 g) [7]. Acceleration is directly propor-
tional to muscle forces generated, which is proportional
to energy expenditure [8]. This theory along with an in-
built algorithm allows for the conversion of acceleration
into activity counts. These counts can be classified into
thresholds, indicating light, moderate or heavy intensity
levels [8]. Accelerometers are able to track intensity,
duration and frequency of an activity without relying on
patient recall [9]. Actical accelerometers in particular,
can detect varying levels of activity, being able to detect
lower level activities and movement in multiple planes
[7] and may therefore be an ideal tool for measuring
physical activity and sedentary behaviour in patients
with RA, where most movement is functional and of a
low frequency and intensity, and therefore unlikely to be
reported accurately using self report measures. Indeed
accelerometry has already been used to this effect in
other rheumatic diseases [10]. Although there is a pau-
city of research which has objectively assessed physical
activity levels in people with RA, our group, as well as
Semanik et al. [11] have recently demonstrated that seden-
tary behaviour as assessed using accelerometery is indeed
more prevalent in patients with RA when compared to
their healthy counterparts [12].
Patients with RA have lower bone mineral density
(BMD) at the hip, spine, and whole body than agematched controls [13]. Lower BMD and higher incidence
of osteoporosis in patients with RA may be as a result of
the presence of circulating inflammatory cytokines inher-
ent to the disease, the decreased mobility of these patients,
or due to certain medications taken to treat the disease
such as corticosteroids. Osteoporosis in RA can be gener-
alised or peri-articular in nature. Studies have shown that
the majority of bone density loss in RA occurs in the first
six months of disease [14]. Furthermore, patients with
higher RA disease activity have been shown to exhibit a
greater loss in BMD, as well as higher indices of bone me-
tabolism compared to those with lower disease activity.
Mobility and functional ability have been correlated with
BMD; as have age, stature, and sex independently of RA
disease [15,16].
The skeleton transforms it’s mass and morphology ac-
cording to individual activity levels and forces placed
upon the bone [17]. Furthermore a minimum effective
strain must be placed upon bone in order for remodeling
to occur [18]. A sedentary individual does not place suf-
ficient strain on the skeleton, and bones are thus remod-
eled in a direction that promotes bone loss. Patients
with RA are therefore at increased risk of osteoporosis
due to inflammatory processes inherent to their disease;
as well as their sedentary lifestyle [19]. Bone mass in RA
can be modified using treatments designed to increase
bone mass; decrease RA disease activity; and by increas-
ing physical activity or decreasing sedentary behavior
sufficiently in order to increase bone loading and remod-
eling. Research has shown that exercises aimed at in-
creasing or attenuating loss of BMD should be dynamic-
comprised of short and vigorous bouts of high impact
exercise incorporating rest periods [20], yet this type of
exercise is usually not feasible in patients with a chronic,
disabling pain condition such as RA.
Exercise interventions making use of light aerobic ac-
tivity, strength training, and stretching, have produced
varied results in cohorts of RA patients. Most studies
show exercise improves physical fitness and muscle
strength with either no change or improved disease ac-
tivity outcomes [21], however these interventions have
not specifically addressed the problem of low bone mass
in these patients. Whole body vibration (WBV) is a po-
tential novel exercise intervention for people with RA.
WBV therapy is an exercise whereby a mechanical vi-
bration platform produces energy via forced oscillation.
The vibratory waves are then transferred to an individ-
ual via propagation through the feet, legs, trunk and fi-
nally, the head [22]. Although the exact mechanisms
whereby WBV therapy increases BMD are unclear, it is
likely that there are multiple mechanisms at play. WBV
has been shown to activate fluid flow in the caniliculi
and lacunae of bone matrix in rats [23], in a manner
proportional to loading frequency. This fluid flow
Figure 1 Flow diagram of study design.
Prioreschi et al. BMC Musculoskeletal Disorders 2014, 15:403 Page 3 of 7
http://www.biomedcentral.com/1471-2474/15/403creates shear stress on the plasma membrane of osteo-
cytes, bone lining cells, and osteoblasts, which therefore
respond accordingly [20]. WBV thus activates mechano-
transduction in bone and stimulates osteogenesis [23].
Furthermore, muscle forces have been shown to exert the
greatest osteogenic stimulus on bone, and the generation
of these forces through vibration stimulus is likely a con-
tributor to the skeletal adaptations that occur [24]. Vibra-
tory stimuli must sufficiently load bones in order to
increase bone deposition.
WBV has been used to treat osteoporosis in otherwise
healthy populations with low BMD [23], older individ-
uals [25], postmenopausal women [26], athletes at risk
of osteoporosis [27], as well as in other diseased popula-
tions [28] with mainly positive results including in-
creased or attenuated loss of BMD, increases in muscle
strength, improved proprioception and balance, and de-
creased pain and fatigue levels. Furthermore, WBV ther-
apy has been shown to increase peripheral blood flow
[29] as well as cardiovascular performance [30], and
could therefore have an effect on cardiovascular health.
Trans et al. [31], used WBV in patients with knee osteo-
arthritis and found 8 weeks of twice weekly vibration
training to significantly improve knee strength in these
patients, but did not assess BMD. Alentorn-Geli et al.
[32] used a dynamic and static WBV protocol, twice
weekly for 6 weeks in a group of female patients with
fibromyalgia. Patients in this study were divided into a
control group who underwent no therapy, an exercise
group who underwent standard RA exercise therapy
only, and a WBV group who underwent WBV training
on top of the standard exercise therapy. The authors of
this study found that the WBV protocol significantly im-
proved fatigue scores, as well as pain scores in compari-
son to the exercise group and the control group,
however no measures of BMD were taken. Other studies
have shown WBV therapy to have no effect on BMD in
healthy adults [33], or on fatigue or pain levels, balance,
or strength [34].
WBV has not, to our knowledge, been used as an exer-
cise intervention for RA, yet it may be a feasible means to
increase functional ability in these patients. Since patients
with RA are already at risk for developing osteoporosis,
and are therefore at greater risk of fracture; WBV could
also potentially be a means to attenuate the progressive
loss of BMD observed in patients with RA, without the
need for a vigorous exercise programme. Previous studies
that have used WBV in other chronic inflammatory or
pain conditions do not suggest that WBV would elicit any
adverse effects in this population. With this background in
mind, the aims of this study are primarily to determine
the effects of a WBV programme on functional ability in
patients with established RA in comparison to a control
group of patients, as well as to determine any effects WBVtherapy may have on BMD, disease activity, physical activ-
ity levels, HRQoL, or body composition in these patients.
Methods
Study design
A semi randomised, single blinded, controlled, two-group
parallel design in accordance with the 2010 CONSORT
guidelines will be used; with patients being allocated to
either group in an alternating manner upon enrollment.
Patients in the WBV group will begin a WBV therapy
intervention programme for a three month period, while
those in the CON group will continue to receive standard
care for the three month period. All patients will be
assessed at three time points, as shown in Figure 1.
Participants
Fifty participants will be recruited from the Rheumato-
logy Clinic at the Chris Hani Baragwanath Academic
Hospital in Soweto, South Africa. Recruitment will
include the outpatients attending the clinic at the quar-
terly check-up via a brief interview following dissemin-
ation of study information. Consenting patients will be
included if they are older than 18 years, have been diag-
nosed with RA (according to the 1987 ACR criteria [35])
at least three years previously, are on stable drug therapy
(prednisone <10 mg/day), and had been for at least three
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HIV+, are using bisphosphonates or corticosteroids,
have any co-morbidities that could potentially impact on
physical activity levels, are using assistive walking de-
vices, have previously had hip or knee joint replacement
surgery, and if they are pregnant.
Ethical consideration
This study complies with the international ethical guide-
lines for a clinical study. Ethical approval has been ob-
tained from the Human Research Ethics Committee of
the University of the Witwatersrand (M130113). Patients
will be required to read and sign informed consent, and
revocation of consent will not detriment the patients in
any way.
Trial registration
This study has been registered with the Pan African
Clinical Trial Registry and has the trial number
PACTR201405000823418 (http://www.pactr.org).
Intervention and control
All vibration training will be performed on standard
power plates (DKN XG 5.0, DKN Technology, California,
USA) under the supervision of the primary investigator.
Vibration training will consist of 24 total sessions (per-
formed twice weekly for 12 weeks); in intermittent
bouts of 60 seconds on the plate and 30 seconds off the
plate, repeated 10 times (this protocol was designed to
stimulate greater osteogenic responses due to the con-
stant stimulus to the mechanoreceptors [27]). Patients
will be required to stand on the plates, barefoot and
with knees slightly bent, holding firmly to the bars. Vi-
bration plates will be set at a constant frequency of
30Hz and amplitude of 3 mm in order to maximize the
osteogenic and muscle activation effects of the therapy
[27]. The CON group will continue to receive standard
care for the intervention period, and will be instructed
to continue with their normal daily activities for the
three month period.
Sample size
A sample size calculation (ß = 0.10) based on detecting a
minimum clinically important difference of 0.22 in HAQ
score (using an SD of 0.19) [36] between the two groups,
showed that at a 5% level we would require a sample of
8 participants in each group with a power of 90%.
Outcome measures
All outcomes will be measured at baseline, and reas-
sessed after the three month intervention, as well as
again three months post intervention. The primary out-
come of this study will be an improvement in functional
ability as assessed by the HAQ. The secondary outcomeswill be attenuation in loss of BMD at the hip, as well as
improvements in subjective pain scores, SF-36, CDAI,
and objective habitual physical activity levels (Table 1).
Primary
Functional ability
Patients will be asked to complete the modified Health
Assessment Questionnaire (HAQ) [37], which is a RA
specific questionnaire that assesses functional ability by
providing a score of functionality between 0 and 3,
where 0 indicates good functionality and 3 indicates se-
vere functional disability.
Secondary
The secondary outcomes of the study are attenuation in
loss of BMD, as well as any improvements in HRQoL, dis-
ease activity, habitual physical activity or body compos-
ition measurements. These will be assessed as follows:
BMD
All patients will be assessed, for site specific areal BMD
at the left hip, lumbar spine (L1-L4), and whole body
using Dual X-Ray Absorbtiometry (DXA). T and Z
scores will then be calculated according to reference
values. All scans will be performed by the same qualified
technician on the same machine (Hologic QDR 4500A,
Hologic, Boston, USA). The machine is routinely calibrated,
and a phantom spine will be scanned daily to determine co-
efficients of variation of the machine. The technician will
be blinded as to the grouping of participants during the
study. According to previous studies examining bone loss
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the effects of exercise interventions on this type of bone
loss [39]; we expect a decrease of approximately 0.33% in
hip BMD in the control group, and for this loss to at least
be attenuated in the WBV group.
Physical activity
At the first assessment, during the last week of the inter-
vention, and again at the follow up assessment, patients
will be fitted with an Actical (Respironics Inc., Murrysville,
PA, USA) accelerometer (for the assessment of habitual
physical activity) worn on a Velcro belt on the hip for a
one week period. Patients will be instructed to wear the
accelerometer all day, and to remove the device only while
sleeping, bathing or showering. Patients will then return
the accelerometer to the clinic one week later. Actical
data are reported in one minute epochs and raw data
are reduced by removing full days of non-wear time by
visual inspection of the data where a full day of con-
secutive zero activity counts are observed. Sleep time is
also removed by visual inspection of the data, and the
remaining data will be considered as wear time. Thereafter,
a valid day will require at least ten hours of wear time per
day, and at least four valid days will be required for inclu-
sion in the final analysis [40]. Data will be reported as aver-
age activity counts per day, as well as percentage of time
spent in sedentary, light, moderate and vigorous activity
thresholds, as calculated by the inbuilt algorithm on the
Actical software. The number of bouts of activity, as well as
the number of breaks in sedentary activity per day will also
be reported, the methodology of which has been explained
previously [41]. Participants will be fitted with the same
Actical at each visit in order to minimise inter-device vari-
ability. This will allow for the assessment of habitual phys-
ical activity patterns before and after the intervention.
Disease activity
Patients will be assessed for disease activity using the
Compound Disease Activity Index (CDAI) [42] which
provides a score comprised of tender joint count (TJC),
swollen joint count (SJC), patient global assessment
(PGA), and physician global assessment (MGA) calcu-
lated as follows:
CDAI ¼ TJCþ SJCþ PGAþMGA
This score allows for the classification of patients
according to the severity of their disease where a score <2.8
indicates remission, a score <10 indicates moderate
disease activity, a score <22 indicates moderate disease
activity, and a score >22 indicates severe disease acti-
vity. The physician will be blinded as to the grouping of
participants during assessments.Inflammation
Patients will be assessed for acute inflammation by
measuring C-reactive protein (CRP) concentration from
a 10 ml venous sample.
Pain
At each assessment, patients will be asked to rate their
pain levels over the previous week using a Lickert scale
ranging from 0–5, where a score of 0 indicates no pain
and a score of 5 indicates unbearable pain. Furthermore,
at each WBV session, patients will be asked to rate their
pain levels on that day using the same Lickert scale.
Fatigue
At each assessment, patients will be asked to rate their
fatigue levels over the previous week using a Lickert
scale ranging from 0–5, where a score of 0 indicates not
feeling tired at all, and a score of 5 indicates the most
tired ever felt.
Anthropometry
Height and weight will be measured to the nearest cm
and kg respectively using a standard stadiometer and
scale, with patients barefoot and wearing minimal cloth-
ing. Thereafter body mass index (BMI) will be
calculated.
Body composition
Body composition, including fat mass and lean muscle
mass will be taken from the DXA scan. Percentage body
fat and percentage lean muscle mass will then be calcu-
lated. Appendicular lean mass (ALM) will also be calcu-
lated and used to classify those patients with sarcopenia.
Statistical analysis
Statistical analysis will be carried out using Stata version
12/IC 12.0. All data will be presented as mean ± SD, and
a p value ≤0.05 will be considered significant. Data will
be analysed on an intention to treat basis. Student’s un-
paired t-tests will be used to compare absolute, as well
as change in HAQ, BMD, physical activity, patient char-
acteristics, and RA disease activity data between the
WBV group and CON group at baseline. Cohen’s D ef-
fect sizes will be calculated to determine the magnitude
of effects observed.
Potential obstacles
Potential obstacles include adherence to the protocol,
and attempting to minimise the attrition rate of the
study. Participants will be in regular contact with the
primary investigator who will attempt to minimise attri-
tion, as well as follow up on patient’s health on a weekly
basis. The short duration of the study, as well as the
intermittent design of the study, lead us to expect an
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analysis by Linke et al. in 2009 [43]. There is the poten-
tial that WBV may cause adverse effects or may not be
tolerated in some participants; however the primary in-
vestigator will observe every WBV session, and assess
pain levels at each WBV session in order to monitor this.
It is also possible that WBV will have no effect on the
outcomes measured.
Discussion
The present study will contribute to the current field
of rheumatology by potentially providing a non-
pharmacological means to improve functional ability
and attenuate the loss of BMD associated with RA.
This study may provide a safe, sustainable exercise
intervention for these patients that could potentially
improve certain aspects of disease activity, as well as
HRQoL and habitual physical activity.
The advantages of the present study over previous exer-
cise interventions in RA include, firstly, the use of a novel
therapy in RA. WBV therapy has not previously been used
in patients with RA (to the best of our knowledge), and
could provide a safe and easy form of exercise for patients
who are often unable to participate in strenuous activities.
Furthermore, the application of an intermittent WBV
programme could potentially exhibit the added benefit
over the previous HRQoL and strength benefits seen fol-
lowing WBV therapy in other rheumatic diseases, of at-
tenuating BMD loss in these patients. Very few studies
have focused exercise interventions on improving or at-
tenuating the loss in BMD in this population, despite the
very high prevalence of osteoporosis that exists. Usually,
interventions designed to increase BMD are dynamic and
strenuous, which is not feasible in an RA population.
WBV therapy could provide a solution to this problem.
Secondly, the use of an objective measurement of phys-
ical activity could further elucidate the benefits of the
WBV intervention by providing an accurate, and detailed
description of changes that may occur during and follow-
ing the WBV intervention. Accelerometry allows for the
novel examination of changes in patterns of habitual phys-
ical activity in this population following the intervention,
which will help elucidate which thresholds of physical ac-
tivity are affected by WBV therapy. Previous research con-
ducted by the authors has shown by using accelerometry
for the first time in this population as a means to compare
physical activity levels to healthy control participants, that
patients with RA are extremely sedentary, and that pa-
tients with higher levels of physical activity fare better on
certain disease activity and HRQoL outcomes [12]. The
potential ability of WBV therapy to increase physical activ-
ity levels could therefore attribute to any changes seen in
functional ability, BMD, disease activity and HRQoL in
the present study.Lastly, the inclusion of a post intervention assessment
allows the sustainability of the present protocol to be ex-
amined. If any changes are observed in any of the primary
or secondary outcomes of the present study, it is import-
ant to be able to report on whether these changes will be
sustained after cessation of the intervention, thereby add-
ing strength to the feasibility of the intervention.
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